Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series

Alchiede Simonato, Michele Billia, Lampropoulou, Brunelli, Riccardo Schiavina, Petralia, Favilla, Corti, Filiberto Zattoni, Claudio Simeone, Alessandro Volpe, Alessandro Antonelli, Nicola Longo, Carlo Terrone, Strada, Castelli, Elisabetta Costantini, Lorenzo Masieri, Andrea Minervini, ValottoRoscigno, Giacomo Novara, Oneto, Stefano Ciciliato, Ottavio De Cobelli, Paolo Gontero, Alchiede Simonato, Ciro Imbimbo, Sergio Cosciani Cunico, Sergio Serni, Giuseppe Morgia, Alessandro Tizzani, Guido Martignoni, Vincenzo Mirone, Zucchi, Siracusano, Giuseppe Martorana, Roberto Bertini, Vincenzo Ficarra, Rocco, Giorgio Carmignani, Porena, Walter Artibani, Francesco Montorsi, Fontana, Marco Carini, Virginia Varca, Sebastiano Cimino

Research output: Contribution to journalArticlepeer-review

69 Citations (Scopus)

Abstract

OBJECTIVESTo investigate cancer-related outcomes of chromophobe renal cell carcinoma (ChRCC) in a large multicentre dataset.To determine prognostic factors for recurrence-free survival (RFS) and cancer-specific survival (CSS) for this RCC histological type.PATIENTS AND METHODSIn all, 291 patients with ChRCC were identified from a multi-institutional retrospective database including 5463 patients who were surgically treated for RCC at 16 Italian academic centres between 1995 and 2007.Univariable and multivariable Cox regression models were used to identify prognostic factors predictive of RFS and CSS after surgery for ChRCC.RESULTSAt a median follow-up of 44 months, 25 patients (8.6%) had disease recurrence and 18 patients (6.2%) died from disease.The 5-year RFS and CSS rates were 89.3% and 93%, respectively.Gender (P = 0.014), clinical T stage (P = 0.017), pathological T stage (P = 0.003), and sarcomatoid differentiation (P = 0.032) were independent predictors of RFS at multivariable analysis.For CSS, there was an independent prognostic role for gender (P = 0.032) and stage (P = 0.019) among the clinical variables and for T stage (P = 0.016), N/M stage (P = 0.023), and sarcomatoid differentiation (P = 0.015) among the pathological variables.CONCLUSIONSPatients with ChRCC have a low risk of tumour progression, metastasis, and cancer-specific death.Patient gender, clinical and pathological tumour stage, and sarcomatoid differentiation are significant predictors of RFS and CSS for ChRCC.
Original languageEnglish
Pages (from-to)76-83
Number of pages8
JournalBJU International
Volume110
Publication statusPublished - 2012

All Science Journal Classification (ASJC) codes

  • Urology

Fingerprint Dive into the research topics of 'Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series'. Together they form a unique fingerprint.

Cite this